Safety Reporting

Current section refers to the item 4.11 Safety Reporting of the INTEGRATED ADDENDUM TO ICH E6(R1): GUIDELINE FOR GOOD CLINICAL PRACTICE E6(R2). It provides an overview of requirements for reporting of Serious Adverse Events occurring during a clinical trial.

 

4.11.1 All serious adverse events (SAEs) should be reported immediately to the sponsor except for those SAEs that the protocol or other document (e.g., Investigator's Brochure) identifies as not needing immediate reporting. The immediate reports should be followed promptly by detailed, written reports.

The immediate and follow-up reports should identify subjects by unique code numbers assigned to the trial subjects rather than by the subjects' names, personal identification numbers, and/or addresses.

The investigator should also comply with the applicable regulatory requirement(s) related to the reporting of unexpected serious adverse drug reactions to the regulatory authority(ies) and the IRB/IEC.

4.11.2 Adverse events and/or laboratory abnormalities identified in the protocol as critical to safety evaluations should be reported to the sponsor according to the reporting requirements and within the time periods specified by the sponsor in the protocol.

4.11.3 For reported deaths, the investigator should supply the sponsor and the IRB/IEC with any additional requested information (e.g., autopsy reports and terminal medical reports).

Clinical Research News

Pfizer testerà un nuovo vaccino pneumococcico per i bambini che necessitano di una vaccinazione di recupero (catch-up)
Il trattamento della tubercolosi è una lunga maratona. Un nuovo studio verificherà se può essere ridotto a 17 settimane
Dopo la diagnosi di diabete di tipo 1 inizia la corsa contro il tempo. Un nuovo studio cercherà di preservare l'insulina naturale
Quanto deve essere basso il colesterolo "cattivo"? Uno studio testa un nuovo target per i pazienti ad altissimo rischio
DYNE-251 testato in uno studio di Fase 3 su pazienti con Distrofia Muscolare di Duchenne
GLP-1 orale testato in persone con diabete di tipo 2 che digiunano durante il Ramadan
Una semplice precauzione da non trascurare: uno studio testa avvisi intelligenti per la prevenzione della preeclampsia

Prossimi studi clinici

Clinical Research Jobs

More jobs

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi